性感裸体美女国产二区,日韩无码专区AV影音,涩涩久热在线

Pfizer Full Year 2025 Financial Report Pfizer Pfizer’s 2025 financial results show a 2% decline in revenue, driven by lower COVID-19 product sales. Non-COVID products and a strong R&D pipeline drive growth. The company projects steady performance with key catalysts in 2026.
Global Biopharma Layoffs December 2025 Layoffs This article tracks recent biotech and pharma layoffs, including major workforce cuts at Voyager Therapeutics, Intercept Pharmaceuticals, Mythic Therapeutics, Pfizer, and others, as companies restructure operations, streamline pipelines, and refocus resources amid shifting market conditions.
Global Biopharma Layoffs August 2025 Layoffs The biopharmaceutical industry sees major August layoffs, with companies like Moderna, Merck cutting jobs amid restructurings, trial setbacks, and M&A activity.
Pfizer 2025 H1 Report Financial statements Pfizer reported $28.4B in revenue for H1 2025, driven by $1.5B in ADC product sales and strong oncology growth. With $13B in BD firepower, Pfizer eyes long-term expansion across key therapeutic areas.
Pfizer Secures Global Rights to SSGJ-707: A Next-Gen PD-1/VEGF Bispecific for Cancer Treatment Pfizer Pfizer acquires global rights to SSGJ-707, a PD-1/VEGF bispecific antibody from 3SBio, aiming to enhance its oncology pipeline with a novel mechanism and strong clinical potential.
Pfizer's Strategic Bet on Bispecifics Pfizer Pfizer commits up to $6B for rights to SSGJ-707, a PD-1xVEGF bispecific, after in-depth due diligence in China. The asset is expected to complement Pfizer’s ADC portfolio and advance its oncology strategy.
FDA Requests COVID-19 Vaccine Label Updates on Heart Risks Moderna The FDA has requested Pfizer/BioNTech and Moderna update COVID-19 vaccine labels to reflect myocarditis and pericarditis risks in males aged 16-25. This update aligns with new FDA vaccine approval guidelines focusing on high-risk groups.
Pfizer's Talzenna Label Bid Faces Setback FDA The FDA’s advisory committee unanimously rejected Pfizer’s proposal to expand Talzenna’s use for prostate cancer patients without HRR mutations, citing insufficient evidence from the TALAPRO-2 trial.
SK Bioscience Wins Key Patent Battle SK Bioscience SK Bioscience wins a key patent dispute against Pfizer in South Korea, enabling global exports of its 13-valent pneumococcal vaccine. The company plans expansion into Southeast Asia and Latin America while advancing next-gen vaccine R&D.
Head-to-Head Challenge Against Keytruda! 3SBio Launches First Phase III Trial for PD-1/VEGF Bispecific Antibody 3SBio 3SBio launches its first Phase III trial for PD-1/VEGF bispecific antibody SSGJ-707 in NSCLC, challenging Keytruda head-to-head, and licenses global rights (ex-China) to Pfizer in a $6.05B deal.

<Pre12 3 Next >

Articles Archives

Hot Articles

All Categories

Agri & Industry Cosmetic Laboratory Pharmaceutical Food

国产91视频久久,亚洲综合色图在线观看,五月天操逼网,日韩色色AV,青青在线A片,亚洲最大色在线观看,欧美熟妇丝袜诱惑,青青操逼视频,日韩无码操出水